Background/Aim: Sorafenib is currently the only medical treatment with proven efficacy
against hepatocellular carcinoma (HCC). HCC cell lines display heterogeneous sensitivity to …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …

Objective Although sorafenib, a molecular targeted agent, has survival benefits for advanced
hepatocellular carcinoma (HCC) patients, its disease control rate remains limited. To explore …

The treatment responses of sorafenib in hepatocellular carcinoma are modest which may be
due to different characteristics of cancer cells or insufficient therapeutic concentrations. This …

The multikinase inhibitor sorafenib is the only effective drug in advanced cases of
hepatocellular carcinoma (HCC). However, response differs among patients and …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most
challenging malignancies of worldwide importance. In fact, HCC is the fifth most common …

Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide.
Hepatocarcinogenesis is associated with deregulation of the cell signaling thus targeted …